In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest
 
    Supporting Improved Patient Onboarding and Adherence with Training Solutions
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
 
    Enhancing The Patient Experience for Self-Injection Systems
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
 
    The Current State of Play in Connected Devices
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation, Product Solutions
 
    Aptar Pharma discusses challenges and benefits of drug repurposing
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
